interesting because all I've seen AI make him do is quit his job to become a "prompt engineer" and sit in front of a computer for hours to waste GPU cycles on making "Minions Looking Like Gangsters with Purple Drank and Bling, in anime Style" over and over again until it "looks just right"
![pp. 158–74 Recently, the scientific consensus has moved in the direction of greater certainty of a significant global warming due to anthropogenic emission of greenhouse gases. See S. Schneider, Laboratory Earth: The Planetary Gamble We Can’t Afford to Lose (New York: Basic Books, 1997); T. R. Karl, N. Nicholls, and J. Gregory, “The Coming Climate,” Scientific American, May 1997, 78–83; and John Houghton, Global Warming: The Complete Briefing (Oxford: Lion Books, 1994). The fact remains, however, that we have as yet no unequivocal signal, that is, a measurement or a series of climate events that all or most atmospheric scientists agree is the signal, of global warming of anything like the magnitude predicted by the available climate models. The atmosphere has in fact cooled, according to the most reliable measurements (by satellites), about o.i°C since 1979. It is almost certain that anthropogenic greenhouse gases added to the atmosphere at the present rate will eventually warm the planet; but at what rate, by how much, with what sort of geographic variation, and with what specific climatic consequences remain questions in need of much better answers than we have. Were not politics involved (which would of course be impossible), there would be much more research and much less posturing. Because it was a project supported by the Competitive Enterprise Institute, a collection of essays entitled The True State of the Planet (ed. Ronald Bailey [New York: Free Press, 1995]) is dismissed out of hand by ecoradicals and ecopoliticians; but its authors include distinguished scientists and economists and it is worth reading on environmental issues like this.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreiaxsiefgrhjtgmomkzee4xedqeplqhd4e7gy2b6jhgyy6exjtmbsi)
![A drawing of Deleuze and Guattari on the left with protestors from May 1968 drawn behind them, and Gregory Bateson drawn on the right thinking "Action"?. The text next to him is not legible. On the right is the following quote:
The scientist as such has no revolutionary potential; he is the first integrated agent of integration, a refuge for bad conscience, and the forced destroyer of his own creativity. Let us consider the more striking [than Andre Grosz] example of a carrie 're a' l'ame 'ricaine) with abrupt mutatiions, just as we imagine such a career to be: Gregory Bateson begins by fleeing the civilized world, by becoming an ethnologist and following the primitive codes and the savage flows; then he turns in the direction of flows that are more and more decoded, those of schizophrenia, from which he extracts an interesting psychoanalytic theory; then, still in search of a beyond, of another wall to break through, he turns to dolphins, to the language of dolphins, to flows that are even stranger and even more deterritorialized. But where does the dolphin flux end, if not with the basic research projects of the American army, which brings us back to the preperations for war and to the absorption of surplus value. (Deleuze and Guattari, 1983: 257)](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreif7ggpzi4v5ns5m4rlnfn3to2apfzdifkbyltxvcw5j4qhxogpzba)
![In my work, I do not focus on transference. My role consists in helping
the patient develop means of expression and processes of subjectification
that would not exist without the analytic process. Often transference is
nothing more than opposition to the analysis, which Lacanians tend to
use manipulatively.
The patient’s feelings result from the process. For me, they are signs of
what is happening in the course of the analytic process itself, not of a
primal libidinality. The La Borde clinic [where Guattari worked all of his
professional life] provides any number of different paths toward subjectifi-
cation. It does not encourage the creation of a classical transference
situation. So to return to your question,‘what’s left of transference?’: there
are transferential mechanisms that concern parts of the body, and there are
also non-personal machines. But the mechanisms of transference touch the
community of care-givers as much as that of the patients. They concern
the whole gamut of activities through which the patients express them-
selves, which we as care-givers make possible and even encourage, and
which contribute to the production of diverse nuclei of subjectification.
As for what is called ‘negative transference’, when resistance to analysis
is produced, the analysis can in my opinion be stopped, at any point that it
is not working. I do not agree with the myth that everything continues as
usual during ‘negative transference’.This is a myth analysts use to console
themselves. Because it is a question of the production of new nuclei of
expression, and not of the unmasking of pre-existent contents, I think of
my active participation, and that of other personnel or communitarian
elements, as catalytic. Either my work is effective, and I’m a good catalyser,
or it is not, and I’m not, and in that case the process must be interrupted.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreif4em3nssbvidovcfocyxh5slmyzpurzocwi242alprtjk4m4fpgm)
![Physicist Sean M. Carroll has written that the idea of a soul is incompatible with quantum field theory (QFT). He writes that, for a soul to exist,
"[n]ot only is new physics required, but dramatically new physics: Within QFT, there can't be a new collection of 'spirit particles' and 'spirit forces' that interact with our regular atoms, because we would have detected them in existing experiments."[152]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreicma67vo3zvkcpyiajpc4bjgn22rsyfn7ktsjxpflmv55k2p3fuhu)
![People known to have arranged for cryonics upon death include PayPal founders Luke Nosek[69] and Peter Thiel,[70] Oxford transhumanists Nick Bostrom and Anders Sandberg, and transhumanist philosopher David Pearce.[71] Larry King once arranged for cryonics but, according to Inside Edition, changed his mind.[72][73]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreifdvc3c5bxvno2pzwvlsbgzzaryaquzwtjci64cu7weppayesyfea)
![Autism Speaks Inc. is a controversial American non-profit autism awareness organization and the largest autism research organization in the United States.[4][5][6] It sponsors autism research and conducts awareness and outreach activities aimed at families, governments, and the public.[4] It was founded in February 2005 by Bob Wright and his wife Suzanne, a year after their grandson Christian was diagnosed with autism. The same year as its founding, the organization merged with Autism Coalition for Research and Education. It then merged with the National Alliance for Autism Research in 2006 and Cure Autism Now in 2007.
The autism rights movement and neurodiversity advocates do not see autism as a disease that needs to be cured,[7][8] and have criticized Autism Speaks for seeking a cure.[8][9][10][11] The word "cure" was dropped from its mission statement in 2016.[12]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreifop6pgkoudif6tp6hy532geutmeu43uwc2f6yavwlclyrtcqx6ja)
![Robert Charles Wright (born April 23, 1943) is an American lawyer, businessman, lobbyist, and author. He is a former NBC executive, having served as president and CEO from 1986 to 2001, and chairman and CEO from 2001[6] until he retired in 2007.[7] He has been credited with overseeing the broadcast network's expansion into a media conglomerate and leading the company to record earnings in the 1990s.[8] Prior to NBC, he held several posts at General Electric in the 1960s, 70s and 80s. He served as President and CEO of GE Capital, GE Financial Services 1983 to 1986 and served as GE's vice chairman until he retired from that role in 2008.[9]
In 2005, Wright and his wife, Suzanne Wright, founded Autism Speaks.[10] In 2016, after his wife's death from pancreatic cancer, Wright established the Suzanne Wright Foundation, which funds research for pancreatic cancer.[11] Through the Suzanne Wright Foundation, he led the initiative to establish a Health Advanced Research Projects Agency, or HARPA, a government research agency modeled after the U.S. Department of Defense's DARPA.[12] On March 15, 2022, Public Law 117-103 was enacted authorizing the establishment of ARPA-H within the U.S. Department of Health and Human Services.[13]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreig3s47fuistrk46zcrtvid4o7pjsy4fnd5jwjkkz2roz4m5qacp6y)
![The high price per treatment of available gene therapies as currently set by drug companies has raised concerns among payers, patients, physicians and policymakers. For example, at launch, voretigene neparvovec was priced at $425 thousand per eye, and onasemnogene abeparvovec-xioi was priced at $2.1 million per patient. From the perspective of the drug companies, charging high prices for their gene therapy is justified by their potential clinical benefit and the costs, risks and uncertainties of development. The clinical benefits include providing significant gains in longevity or symptom relief over conventional treatments and addressing often unmet needs in the treatment of rare diseases. In general, the clinical development of new drugs is time-consuming and costly. The process from the conception of a new drug to its clinical application may span decades and cost billions of dollars, with the bulk of the cost and time spent conducting later-stage clinical trials, even when these trials require fewer patients to complete than conventional small-molecule drugs [3, 4]. The process is also very risky, with only 13.8% of the therapeutic development programs which enter phase 1 of the approval process completing phases 2 and 3 and reaching approval by the FDA [5]. Sales and the use of new drugs also require the company to meet significant regulatory requirements for safety, efficacy and current good manufacturing standards. Most payers will only include new products under their coverage and reimbursement policies after receiving FDA approval.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:ih7sthvco6mfoljwju4ndkpp/bafkreiapov6bheanmn2vxbk77lxbxid6uwetrqmrj3h6eyq3paq2zbppgq)
